Redwood Pharma AB
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a REDW.ST research report →
Companywww.redwoodpharma.se
Redwood Pharma AB engages in the development of ophthalmic pharmaceutical therapies for unmet market needs. The company's lead development product is RP101, an eye drop that treats severe chronic dry eye disease in post-menopausal women. It uses IntelliGel, a supramolecular smart drug delivery system for development of topical formulation for ophthalmic uses, as well as for administration to the front of the eye.
- CEO
- Martin Vidaeus MBA
- IPO
- 2016
- Employees
- 1
- HQ
- Stockholm, SE
Price Chart
Valuation
- Market Cap
- $3.15M
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 87.41
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -98.20%
- ROIC
- -99.44%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-14,184,581 · -8.78%
- EPS
- $-5.35 · 81.10%
- Op Income
- $-13,508,833
- FCF YoY
- -21.57%
Performance & Tape
- 52W High
- $5.22
- 52W Low
- $0.03
- 50D MA
- $1.19
- 200D MA
- $1.38
- Beta
- 0.41
- Avg Volume
- 0
Get TickerSpark's AI analysis on REDW.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our REDW.ST Coverage
We haven't published any research on REDW.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate REDW.ST Report →